BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CorNova Receives CE Mark Approval for Valecor Platinum(R) Coronary Stent System


6/24/2009 7:34:36 AM

Bookmark and Share

BURLINGTON, Mass., June 23 /PRNewswire/ -- CorNova Inc. today announced that it has received CE mark approval for its Valecor Platinum Coronary Stent System.

The Valecor Platinum is a next-generation cobalt-chromium bare-metal stent. Utilizing a novel ion-based implantation technology called Nanofusion(TM), the Valecor Platinum stent presents a pure platinum surface to both the lumen and artery wall to provide protection from less biocompatible components inherent in all medical-grade alloys. Platinum is known for its superior biocompatibility and biostability. In addition, the stent offers some of the thinnest struts available and a novel open cell design that maximizes flexibility and conformability, while causing minimal inflammation and tissue damage during deployment.

"The Valecor Platinum Coronary Stent System represents a major advancement over current offerings in the relatively undifferentiated $1 billion bare stent market," said S. Eric Ryan, M.D., chairman and chief executive officer of CorNova. "Because of its highly biocompatible platinum surface and its novel open cell design, it has shown superior anti-restentotic performance compared to leading bare metal stents in preclinical studies."

About CorNova

CorNova is a developer of next-generation endovascular products designed to integrate new technologies into existing products and procedures, resulting in better patient outcomes without added procedure time, cost and patient risk. The company's FiberHalo(TM) stent deployment and post-dilatation angioplasty balloon catheters are designed to provide stent lumen area measurement within the angioplasty catheter itself. CorNova is also developing a pre-dilatation version of the FiberHalo catheter that can detect the potential of mechanical failure that would allow for treatment prior to stent placement and the Valecor Platinum(TM) Coronary Stent, an advanced "bare-metal stent" with an ion-infused pure platinum surface that has shown superior performance and anti-restenoic properties compared to current bare-metal stents. For more information, visit www.cornova.com.

Read at BioSpace.com

CorNova
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES